<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39319092</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Protection of Omicron Bivalent Vaccine, Previous Infection, and Their Induced Neutralizing Antibodies Against Symptomatic Infection With Omicron XBB.1.16 and EG.5.1.</ArticleTitle><Pagination><StartPage>ofae519</StartPage><MedlinePgn>ofae519</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofae519</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofae519</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Data are limited on the protective role of the Omicron BA bivalent vaccine, previous infection, and their induced neutralizing antibodies against Omicron XBB.1.16 and EG.5.1 infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a nested case-control analysis among tertiary hospital staff in Tokyo who had received ≥3 doses of COVID-19 vaccines and donated blood samples in June 2023 (1 month before the Omicron XBB.1.16 and EG.5.1 wave). We identified 206 symptomatic cases between June and September 2023 and selected their controls with 1:1 propensity score matching. We examined the association of vaccination, previous infection, and preinfection live virus neutralizing antibody titers against Omicron XBB.1.16 and EG.5.1 with the risk of COVID-19 infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Previous infection during the Omicron BA- or XBB-dominant phase was associated with a significantly lower infection risk during the XBB.1.16 and EG.5.1-dominant phase than infection-naive status, with 70% and 100% protection, respectively, whereas Omicron BA bivalent vaccination showed no association. Preinfection neutralizing titers against XBB.1.16 and EG.5.1 were 39% (95% CI, 8%-60%) and 28% (95% CI, 8%-44%) lower in cases than matched controls. Neutralizing activity against XBB.1.16 and EG.5.1 was somewhat detectable in the sera of individuals with previous infection but barely detectable in those who were infection naive and received the Omicron bivalent vaccine.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In the era when the Omicron XBB vaccine was unavailable, the Omicron BA bivalent vaccine did not confer the neutralizing activity and protection against Omicron XBB.1.16 and EG.5.1 symptomatic infection. The previous infection afforded neutralizing titers and protection against symptomatic infection with these variants.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Shohei</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6503-8577</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Kouki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizoue</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1198-2228</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horii</LastName><ForeName>Kumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Infection Control Office, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okudera</LastName><ForeName>Kaori</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Infection Control Office, Kohnodai Hospital of the National Center for the Global Health and Medicine, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Tomofumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oshiro</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inamura</LastName><ForeName>Natsumi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemoto</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S Takeuchi</LastName><ForeName>Junko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konishi</LastName><ForeName>Maki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiyama</LastName><ForeName>Haruhito</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoyanagi</LastName><ForeName>Nobuyoshi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Kohnodai Hospital of the National Center for the Global Health and Medicine, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiura</LastName><ForeName>Wataru</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmagari</LastName><ForeName>Norio</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4622-8970</Identifier><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">bivalent vaccine</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword><Keyword MajorTopicYN="N">previous infection</Keyword><Keyword MajorTopicYN="N">protection</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. All authors: No reported conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39319092</ArticleId><ArticleId IdType="pmc">PMC11420683</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofae519</ArticleId><ArticleId IdType="pii">ofae519</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack  FP, Thomas  SJ, Kitchin  N, et al.  Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med  2020; 383:2603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden  LR, El Sahly  HM, Essink  B, et al.  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med  2021; 384:403–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng  M-Q, Li  R, Weng  Z-Y, Song  G. Relative effectiveness of bivalent COVID-19 vaccine: a systematic review and meta-analysis. Front Med (Lausanne)  2024; 10:1322396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10879625</ArticleId><ArticleId IdType="pubmed">38384317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura  T, Ito  J, Uriu  K, et al.  Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun  2023; 14:2800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10187524</ArticleId><ArticleId IdType="pubmed">37193706</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasoba  D, Uriu  K, Plianchaisuk  A, et al.  Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect Dis  2023; 23:655–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10156138</ArticleId><ArticleId IdType="pubmed">37148902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku  Y, Kosugi  Y, Uriu  K, et al.  Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5. Lancet Infect Dis  2023; 23:e395–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">37708910</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang  J, Hong  W, Lei  H, et al.  Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection. Signal Transduct Target Ther  2023; 8:252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10279763</ArticleId><ArticleId IdType="pubmed">37336889</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang  Q, Guo  Y, Zhang  RM, et al.  Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect Dis  2023; 23:e397–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">37708906</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang  L, Kempf  A, Nehlmeier  I, et al.  Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3. Lancet Infect Dis  2023; 23:e391–2.</Citation><ArticleIdList><ArticleId IdType="pubmed">37716358</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan  CY, Chiew  CJ, Pang  D, et al.  Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. Lancet Infect Dis  2023; 23:799–805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10306341</ArticleId><ArticleId IdType="pubmed">36924786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei  J, Stoesser  N, Matthews  PC, et al.  Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population. Nat Commun  2024; 15:1008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10837445</ArticleId><ArticleId IdType="pubmed">38307854</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha  NK, Burke  PC, Nowacki  AS, Simon  JF, Hagen  A, Gordon  SM. Effectiveness of the coronavirus disease 2019 bivalent vaccine. Open Forum Infect Dis  2023; 10:ofad209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10234376</ArticleId><ArticleId IdType="pubmed">37274183</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto  S, Oshiro  Y, Inamura  N, et al.  Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine. Clin Microbiol Infect  2023; 29:1201.e1–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10207835</ArticleId><ArticleId IdType="pubmed">37236545</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto  S, Maeda  K, Matsuda  K, et al.  Coronavirus disease 2019 (COVID-19) breakthrough infection and post-vaccination neutralizing antibodies among healthcare workers in a referral hospital in Tokyo: a case-control matching study. Clin Infect Dis  2021; 75:e683–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755292</ArticleId><ArticleId IdType="pubmed">34950947</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto  S, Matsuda  K, Maeda  K, et al.  Preinfection neutralizing antibodies, Omicron BA.5 breakthrough infection, and long COVID: a propensity score–matched analysis. J Infect Dis  2023; 228:1652–61.</Citation><ArticleIdList><ArticleId IdType="pubmed">37756608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawase  M, Shirato  K, van der Hoek  L, Taguchi  F, Matsuyama  S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol  2012; 86:6537–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3393535</ArticleId><ArticleId IdType="pubmed">22496216</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya  K, Maeda  K, Matsuda  K, et al.  Neutralization activity of IgG antibody in COVID-19–convalescent plasma against SARS-CoV-2 variants. Sci Rep  2023; 13:1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9869318</ArticleId><ArticleId IdType="pubmed">36690803</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizoue  T, Yamamoto  S, Konishi  M, et al.  Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research center in Tokyo after the emergence of variants. Epidemiol Infect  2023; 151:1–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10063865</ArticleId><ArticleId IdType="pubmed">36960731</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu  Y, Zou  J, Kurhade  C, et al.  Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1. Emerg Microbes Infect  2023; 12:2271089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10606781</ArticleId><ArticleId IdType="pubmed">37824708</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryawanshi  R, Ott  M. SARS-CoV-2 hybrid immunity: silver bullet or silver lining?  Nat Rev Immunol  2022; 22:591–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362961</ArticleId><ArticleId IdType="pubmed">35945353</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraone  JN, Liu  S-L. Immune imprinting as a barrier to effective COVID-19 vaccines. Cell Rep Med  2023; 4:101291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10694758</ArticleId><ArticleId IdType="pubmed">37992689</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>